A Comparative Study of Percutaneous Pulsed Field Ablation Guided by Ultrasound Alone Versus Fluoroscopy in Patients With Atrial Fibrillation
2026년 8월 11일 업데이트: China National Center for Cardiovascular Diseases
This prospective, randomized, multicenter, open-label, non-inferiority interventional study aims to compare the therapeutic efficacy of percutaneous pulsed field ablation (PFA) guided by ultrasound alone versus fluoroscopy in patients with paroxysmal atrial fibrillation (AF).
The success rate of complete electrical isolation of pulmonary veins during the procedure was compared to verify that ultrasound-only guidance is non-inferior to fluoroscopic guidance.
연구 개요
상태
아직 모집하지 않음
연구 유형
중재적
등록 (추정된)
276
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: MIN TANG, Doctor
- 전화번호: 86+ 13810665178
- 이메일: doctordangmin@sina.com
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Adult patients aged 18 to 75 years (including 18 years and 75 years of age).
- Patients diagnosed with paroxysmal atrial fibrillation via 12-lead electrocardiography or ambulatory electrocardiography and scheduled to undergo pulsed field ablation.
- Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program.
Exclusion Criteria:
- Atrial fibrillation secondary to electrolyte imbalance, thyroid disorders, or reversible non-cardiac causes;
- Previous history of catheter ablation or cardiac surgery for atrial fibrillation;
- Prior surgical history including patent foramen ovale closure, atrial septal defect closure or repair;
- Implantation of left atrial appendage occluder, mechanical mitral valve prosthesis, or valvuloplasty ring containing metallic materials;
- Concomitant other tachyarrhythmias requiring catheter ablation (e.g., atrioventricular reentrant tachycardia, atrioventricular nodal reentrant tachycardia, atrial tachycardia, atrial flutter, Wolff-Parkinson-White syndrome, etc.);
- Persistent atrial fibrillation;
- Left atrial anteroposterior diameter (LAD) > 55 mm on transthoracic echocardiography;
- Women who are pregnant, breastfeeding, or of childbearing age with plans to become pregnant during the clinical trial;
- Current participation in another pharmaceutical or medical device clinical study.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Percutaneous pulsed field ablation performed under ultrasound-only guidance.
Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation.
|
Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation.
|
|
활성 비교기: Pulsed field ablation performed under fluoroscopic guidance
Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance.
|
Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Success rate of complete electrical isolation of pulmonary veins during the procedure
기간: Immediately post-procedure
|
The proportion of all pulmonary veins maintaining bidirectional block across ablation lines at 20 minutes after ablation completion.
|
Immediately post-procedure
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The incidence of complications within 30 days after the procedure
기간: Within 30 days post-procedure
|
Observe the proportion of complications occurring within 30 days after the procedure.
Such complications include pericardial effusion or cardiac tamponade requiring drainage, phrenic nerve palsy lasting more than 24 hours, severe vascular complications requiring intervention, stroke/transient ischemic attack, atrioesophageal fistula, and death.
|
Within 30 days post-procedure
|
|
Success rate of atrial fibrillation ablation at 12 months post-procedure.
기간: 12 months post-procedure
|
Defined as the absence of AF, atrial flutter (AFL), or atrial tachycardia (AT) episodes ≥30 seconds on dynamic electrocardiogram (ECG) monitoring after the blanking period (90 days post-catheter ablation)
|
12 months post-procedure
|
|
The proportion of patients admitted to hospital or emergency departments due to atrial fibrillation recurrence within 12 months after the procedure.
기간: 12 months post-procedure
|
The proportion of patients admitted to hospital or emergency departments due to atrial fibrillation recurrence within 12 months after the procedure.
|
12 months post-procedure
|
|
The proportion of patients who received electrical cardioversion due to atrial fibrillation recurrence within 12 months after the procedure
기간: 12 months post-procedure
|
The proportion of patients who received electrical cardioversion due to atrial fibrillation recurrence within 12 months after the procedure.
|
12 months post-procedure
|
|
The proportion of patients undergoing repeat ablation surgery owing to atrial fibrillation within 12 months after the procedure
기간: 12 months post-procedure
|
The proportion of patients undergoing repeat ablation surgery owing to atrial fibrillation within 12 months after the procedure
|
12 months post-procedure
|
|
The proportion of patients who resumed antiarrhythmic drug therapy during follow-up after the blanking period
기간: From the end of the blanking period (within 90 days after catheter ablation) to 12 months post-procedure
|
The proportion of patients who resumed antiarrhythmic drug therapy during follow-up after the blanking period
|
From the end of the blanking period (within 90 days after catheter ablation) to 12 months post-procedure
|
|
Improvement in the total EQ-5D quality-of-life questionnaire score at 12 months post-procedure compared with baseline
기간: 12 months post-procedure
|
The degree of improvement in total EQ-5D scores at 12 months after ablation relative to baseline levels
|
12 months post-procedure
|
|
Statistical analysis was performed to evaluate differences in fluoroscopic exposure dose between the two groups.
기간: Immediately post-procedure
|
Statistical analysis was performed to evaluate differences in fluoroscopic exposure dose between the two groups.
|
Immediately post-procedure
|
|
Compare the length of hospital stay and postprocedural ICU/CCU stay duration between the two groups.
기간: through study completion, an average of 1 year
|
After hospital discharge, the length of hospital stay for this admission and the duration of postoperative observation in CCU/ICU were compared between the two groups of patients.
|
through study completion, an average of 1 year
|
|
Compare the procedural time and DSA fluoroscopy time between the two groups.
기간: Immediately post-procedure
|
Statistical analyses were performed to compare procedural duration and DSA fluoroscopy duration across the two groups.
|
Immediately post-procedure
|
|
Compare the differences in costs between the two groups, including medical equipment costs, personnel costs, and patient hospitalization expenses.
기간: through study completion, an average of 1 year
|
Total hospitalization costs incurred during this admission were compared between the two groups after hospital discharge.
|
through study completion, an average of 1 year
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2026년 8월 15일
기본 완료 (추정된)
2029년 2월 28일
연구 완료 (추정된)
2029년 2월 28일
연구 등록 날짜
최초 제출
2026년 7월 29일
QC 기준을 충족하는 최초 제출
2026년 8월 11일
처음 게시됨 (실제)
2026년 8월 13일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 8월 13일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 8월 11일
마지막으로 확인됨
2026년 7월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .